AAPG vs ZYME
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AAPG's Piotroski F-Score of 4/9 indicates weak financial health, with no Altman Z-Score available to assess bankruptcy risk. The company exhibits severe profitability issues, with a negative profit margin of -296.77% and ROE of -159.65%, alongside a 71.6% YoY revenue decline. Despite a high gross margin of 90.87%, the business is not generating sustainable earnings. The stock trades at a premium valuation (Price/Book: 79.25) with no intrinsic value or Graham Number, suggesting speculative pricing. Analysts rate it a 'strong_buy' with a target of $49.14, but this is not supported by fundamentals.
ZYME exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating a failing financial trajectory. Despite a strong liquidity position (Current Ratio 5.88) and low debt, the company has suffered a catastrophic revenue collapse of -91.90% YoY. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish insider activity, with executives selling $4.67M in shares. The valuation is speculative, trading at a high Price/Sales multiple of 19.23 despite negative margins and shrinking top-line growth.
Compare Another Pair
Related Comparisons
AAPG vs ZYME: Head-to-Head Comparison
This page compares Ascentage Pharma Group Internat (AAPG) and Zymeworks Inc. (ZYME) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.